Beam Therapeutics shares surge 11.68% premarket after JonesTrading analyst upgrades to Buy.

Beam Therapeutics (BEAM) surged 11.68% in premarket trading, driven by positive developments including the U.S. FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation for its sickle cell disease candidate, BEAM-101, announced on August 14. This regulatory milestone, alongside sustained analyst optimism—such as H.C. Wainwright’s “Buy” rating and Bernstein’s positive outlook—boosted investor confidence. Additionally, Cathie Wood’s ARK Investment Management purchased over 509,600 shares in August, signaling institutional support. While unrelated to the premarket move, Beam Global (BEEM)’s Sourcewell contract for EV infrastructure was mistakenly cited in some summaries, but the primary catalyst for BEAM’s rally was its therapeutic pipeline progress and analyst upgrades.